Amgen Drug Delivers More Weight Loss Than Competitors
A new weight loss drug developed by Amgen may provide better results with fewer injections than current treatments such as ...
New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms
Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed ...
Amgen's weight-loss drug fails to impress in study; shares plunge
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
MM&M1d
Amgen’s MariTide achieves 20% weight loss, but Wall Street remains unimpressed
Amgen released promising results from its Phase 2 trial, but the data led to a significant decline in its stock price as Wall ...
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
Amgen’s MariTide shows up to 20% average weight loss in Phase 2 study
Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart ...
Hold Rating on Amgen’s Maritide Amid Uncertainties in Efficacy and Tolerability
Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Amgen (AMGN – Research Report). The associated price target ...
Amgen’s Stock Outlook: Balancing Maritide’s Weight Loss Data Concerns and Diabetes Treatment Potential
Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.Don't ...
BioSpace1d
‘Bulls Disappointed’ as Amgen’s MariTide Demonstrates 20% Weight Loss
With Amgen’s MariTide results at the lower end of investors’ expectation of 20% to 25% weight loss, the much-anticipated ...
Amgen shows 20% weight loss in once-monthly injectable MariTide
Amgen's latest once-monthly weight loss drug data looks "OK," analysts say, as its path to approval still remains murky.
Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...